SOLAR-PROMOTION-GMBH
8.5.2024 17:40:34 CEST | Business Wire | Press release
The energy industry is undergoing a radical transformation. Renewable sources of energy have become increasingly profitable in recent years and are now the most economically viable solution for generating electricity. Deployment is accelerating and the technologies are becoming increasingly sophisticated. This has put renewables in the fast lane. Visionary companies are contributing to this development with modern technologies, ideas and concepts. The best and most innovative developments have been nominated for The smarter E AWARD 2024. The prize is awarded in five categories: Photovoltaics, Energy Storage, E-Mobility, Smart Integrated Energy and Outstanding Projects. The winners will be honored on the eve of The smarter E Europe on June 18 at 6:15pm at the International Congress Center München (ICM). Europe’s largest alliance of exhibitions for the energy industry unites four exhibitions (Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe) and will take place at Messe München from June 19–21.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508604806/en/
The finalists for The smarter E AWARD 2024 have been announced in the five categories. (© Solar Promotion GmbH)
Intelligent, innovative, interdisciplinary – as Europe’s largest alliance of exhibitions for the energy industry, The smarter E Europe highlights key topics for a renewable 24/7 energy supply. The focus will be on solar energy, storage technologies, electromobility and grid and energy management. The smarter E AWARD is presented every year as part of this exhibition. The innovation prize recognizes companies and their products that are actively shaping tomorrow’s energy world. This year's finalists showcase clear trends – from artificial intelligence and digital twins to software-as-a-service solutions to higher performance and efficiency. These companies are the finalists of The smarter E AWARD 2024.
The finalists of the Photovoltaics category
- Aiko Energy (China)
- ArcelorMittal Construction (France)
- Euronergy (Netherlands)
- Institute for Solar Energy Research ISFH + Aerial PV Inspection (Germany)
- NexWafe (Germany)
- PVcase (Lithuania)
- Shenzhen Hopewind Electric (China)
- SMA Solar Technology (Germany)
- Solar Materials (Germany)
- WAVELABS Solar Metrology Systems (Germany)
The finalists of the Energy Storage category
- Contemporary Amperex Technology Co., Limited (CATL) (China)
- Cubenergy (China)
- Enphase Energy (USA)
- ESS Tech (USA)
- HagerEnergy (Germany)
- Jackery Technology (USA)
- Pfannenberg Europe (Germany)
- Sigenergy Technology Co., Ltd. (China)
- sonnen (Germany)
- Trina Storage (China)
The finalists of the E-Mobility category
- Autel Europe (Germany)
- Designwerk Technologies (Switzerland)
- EcoG (Germany)
- Huawei Digital Power (China)
- Road (Netherlands)
- SolarPaint by Apollo Power (Israel)
- Vector Informatik (Germany)
- XCharge Europe (Germany)
Finalists of the Smart Integrated Energy category
- CyberGrid (Germany)
- Delfos – Intelligence Asset Management (Spain)
- dvlp.energy (Germany)
- Entrix (Germany)
- Off-Grid Europe (Germany)
- PIONIERKRAFT (Germany)
- SolarEdge (Israel)
- suena (Germany)
- The Mobility House (Germany)
Finalists in the Outstanding Projects category
- 3SUN (Italy)
- Beijing HyperStrong Technology (China)
- Boreal Light (Germany)
- CALB Group (China)
- Huawei Digital Power (China)
- IO-Dynamics (Germany)
- LONGi Solar Technology (China)
- MaxSolar (Germany)
- Red Sea Global (Saudi Arabia)
- Siemens (Germany)
For more information, please visit:
www.TheSmarterE-award.com
The smarter E Europe
“Accelerating Integrated Energy Solutions“ – this is the motto of The smarter E Europe. Europe’s largest alliance of exhibitions for the energy industry puts the spotlight on cross-industry solutions for a renewable 24/7 energy supply covering electricity, heat and transport. The smarter E Europe unites four exhibitions and will take place from June 19–21, 2024 at Messe München.
More information: www.TheSmarterE.de
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508604806/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom